Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Phospho-CtIP (Thr847) Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA595666
Description
Antigen Affinity Purified from Pooled Serum.
CtIP, a 125 kD protein, was originally found interacting with a transcription repressor, CtBP, through the PLDLS motif (CtBP-Interacting Protein) thus suggested a role in transcription. Studies have shown that CtIP also interacts with BRCA1 protein through the c-terminus BRCT domains also suggested that CtIP is a potential tumor suppressor. This CtIP-BRCA1 interaction can be disrupted by DNA damaging agents including UV or gamma-irradiation. Li et al (Nature 406, 210 - 215 (2000)) have shown that ATM phosphorylates CtIP at serine residues 664 and 745, and mutation of these sites abrogates the dissociation of BRCA1 from CtIP, resulting in persistent repression of BRCA1-dependent induction of GADD45 upon ionizing radiation.
Specifications
Phospho-CtIP (Thr847) | |
Polyclonal | |
Unconjugated | |
Rbbp8 | |
9930104E21Rik; COM1; CtBP-interacting protein; CtIP; DNA endonuclease RBBP8; JWDS; RB binding protein 8, endonuclease; RBBP8; RBBP-8; retinoblastoma binding protein 8; retinoblastoma-binding protein 8; Retinoblastoma-interacting protein and myosin-like; RGD1308872; RIM; SAE2; SCKL2; Sporulation in the absence of SPO11 protein 2 homolog | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
5932 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot | |
∼0.15 mg/mL | |
10mM HEPES with 100μg/mL BSA, 50% glycerol, 0.15M NaCl and no preservative; pH 7.5 | |
Q99708 | |
Rbbp8 | |
Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr847 conjugated to KLH. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction